RSS | Login | Register

VALSTAR

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare VALSTAR to:

Generic Name for VALSTAR

Valrubicin 40mg/mL; soln for intravesical instillation after dilution; contains 50% polyoxyl castor oil/50% dehydrated alcohol; preservative-free.

Legal Classification:

Pharmacological Class for VALSTAR

Anthracycline.

Manufacturer of VALSTAR

Endo Pharmaceuticals

Indications for VALSTAR

Intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.

Adult dose for VALSTAR

Drain bladder before instilliation. 800mg given intravesically via urethral catheter once weekly for 6 weeks. Retain drug for 2 hours before voiding, then void.

Children's dosing for VALSTAR

Not recommended.

Contraindications for VALSTAR

Concurrent UTI. Small bladder capacity (eg, unable to tolerate a 75mL instillation).

Warnings/Precautions for VALSTAR

Monitor for disease recurrence or progression with cystoscopy, biopsy, and urine cytology every 3 months; if there is not a complete response of CIS to treatment after 3 months or if CIS recurs, cystectomy must be reconsidered. Severe irritable bladder symptoms. Perforated bladder. Bladder mucosa compromised. Delay administration for at least 2 weeks after transurethral resection and/or fulguration. Maintain adequate hydration. Pregnancy (Cat. C); avoid, both males and females should use effective birth control. Nursing mothers: not recommended.

Adverse Reactions for VALSTAR

Bladder symptoms (eg, urinary frequency, dysuria, urinary urgency, spasm, hematuria, pain, incontinence, cystitis, nocturia, local burning, urethral pain, pelvic pain, UTI).

How is VALSTAR supplied?

Single-use vials—4, 24

Related Disease:

Cancer, bladder

Zuplenz oral soluble film approved for nausea and vomiting

July 06, 2010

The FDA has approved Zuplenz (ondansetron oral soluble film, from Strativa) for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

Cysview approved for cystoscopic detection of papillary bladder cancer

June 01, 2010

The FDA has approved Cysview (hexaminolevulinate HCl, from GE Healthcare), an optical imaging agent, for use in the cystoscopic detection of non-muscle-invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

EvoLife products available for cancer patients undergoing chemotherapy and radiotherapy

March 31, 2010

EvoLife Laboratories has launched its product line of skin, oral, nail, hair, hygiene care for cancer patients undergoing chemotherapy and radiotherapy.

FDA cancer drug approval rate reviewed in JNCI

February 19, 2010

The FDA's Office of Oncology Drug Products approved 53 new indications for the use of oncology and hematology drugs and biologics from July 2005 to the end of 2007.